NCT05299281View on ClinicalTrials.gov

Micropulse Transscleral Diode Laser Cyclophotocoagulation (MP-TSCPC) as a Treatment Modality for Glaucoma Patients

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Glaucoma
Interventions
DEVICE

Micropulse transscleral cyclophotocoagulation (MP-TSCPC)

"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."

Trial Locations (1)

13511

Benha University, Banhā

All Listed Sponsors
lead

Benha University

OTHER

NCT05299281 - Micropulse Transscleral Diode Laser Cyclophotocoagulation (MP-TSCPC) as a Treatment Modality for Glaucoma Patients | Biotech Hunter | Biotech Hunter